Department of Pediatrics Archive — Page 29 of 54
-
August 14, 2020
Study finds patients’ access to opioid treatment cumbersome
Women are having a difficult time getting into treatment for opioid addictions, according to a Vanderbilt University Medical Center study published today in JAMA Open. -
August 6, 2020
Patrick receives award for children’s health research
Stephen Patrick, MD, MPH, MS, director of the Vanderbilt Center for Child Health Policy, has been awarded the fifth annual Gale and Ira Drukier Prize in Children’s Health Research. -
July 28, 2020
Post-transplant complication
Vanderbilt researchers conducted the largest analysis to date of a heart complication in children following stem cell transplant. The findings may help guide screening practices to improve outcomes. -
July 24, 2020
Health, well-being and food security of families deteriorating under COVID-19 stress
The ongoing disruptive changes from efforts to reduce the spread of COVID-19 are having a substantial negative impact on the physical and mental well-being of parents and their children across the country, according to a new national survey published today in Pediatrics. -
July 16, 2020
Nearly one-third of Tennessee parents are worried their child has an undiagnosed mental health condition, new poll finds
One-third of Tennessee parents with children ages 6-17 are worried their child has an undiagnosed mental health condition, a new poll from the Vanderbilt Center for Child Health Policy found. -
July 15, 2020
Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial
In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. -
July 14, 2020
VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial
An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.